---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-193453"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2023-07-25T23:59:59+00:00"
generated_at: "2026-06-13T03:10:12.421529+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "high"
source: SEC EDGAR
---

# UroGen appoints James A. Robinson Jr. to Board, increasing size to 9 directors

## Summary
- Board increased from 8 to 9; Robinson appointed to fill vacancy and serve on Compliance Committee.
- Initial option grant of 20,000 ordinary shares, vesting quarterly over 12 quarters.
- Annual retainer of $40,000 plus $5,000 for Compliance Committee service.
- Eligible for annual option grant of 10,000 shares at each annual shareholder meeting.
- Standard indemnity agreement will be entered with Robinson.

## SEC filing metadata
- accession: 0001193125-23-193453
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2023-07-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312523193453/0001193125-23-193453-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312523193453/d480915d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-193453
- JSON: https://secwatch.observer/filing/0001193125-23-193453.json
- Plain text: https://secwatch.observer/filing/0001193125-23-193453.txt

## Key facts
- Executive change
  James A. Robinson Jr. was appointed as Director at UroGen Pharma Ltd..
  - Action: appointed
  - Role: Director
  source text: appointed James A. Robinson Jr. to fill the vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312523193453/0001193125-23-193453-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.